Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1416241

Metastatic refractory undifferentiated small round-cell sarcoma successfully treated with surufatinib and camrelizumab: a case report

Provisionally accepted
Yong Li Yong Li 1,2,3*Jinpeng Huang Jinpeng Huang 1,2,4*Xian Chen Xian Chen 1,2Yongsong Ye Yongsong Ye 5*Xiaohu Du Xiaohu Du 6*Ioannis A Voutsadakis Ioannis A Voutsadakis 7,8Mahesh Seetharam Mahesh Seetharam 9Haibo Zhang Haibo Zhang 1,2*Min Lu Min Lu 1,2,4*
  • 1 Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou , Guangdong, China
  • 2 Department of Oncology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
  • 3 Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Zhuhai, China
  • 4 Other, Zhuhai\, China
  • 5 Other, Guangzhou, China
  • 6 Department of Pathology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China, China
  • 7 Other, Sudbury, Canada
  • 8 Other, Sault Ste Marie,, Canada
  • 9 Other, Phoenix, AZ,, United States

The final, formatted version of the article will be published soon.

    Background: Undifferentiated small round-cell sarcomas (uSRCSs) are a subgroup of sarcomas that are difficult to diagnose. Some uSRCSs have specific gene rearrangements, but others do not. Currently, there is no specific treatments for advanced uSRCSs, and its treatment is largely based on general experience with sarcomas, which A CT scan showed that the tumor achieved a partial response. As of April 2023, the patient had a progression-free survival time of 26 months.Conclusions: Surufatinib in combination with camrelizumab could be effective in the treatment of advanced uSRCSs.

    Keywords: undifferentiated small round-cell sarcoma, surufatinib, Programmed death-1 inhibitor, target therapy, case report

    Received: 12 Apr 2024; Accepted: 12 Jun 2024.

    Copyright: © 2024 Li, Huang, Chen, Ye, Du, Voutsadakis, Seetharam, Zhang and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yong Li, Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou , Guangdong, China
    Jinpeng Huang, Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou , Guangdong, China
    Yongsong Ye, Other, Guangzhou, China
    Xiaohu Du, Department of Pathology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China, China
    Haibo Zhang, Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou , Guangdong, China
    Min Lu, Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou , Guangdong, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.